Preprint Brief Report Version 1 This version is not peer-reviewed

Yin-Yang Balance of ACE/ACE2 Pathways: The Rational for ACE2 Pathway Inhibitor Administration in SARS-CoV-2 Patients

Version 1 : Received: 19 March 2020 / Approved: 23 March 2020 / Online: 23 March 2020 (06:29:42 CET)
Version 2 : Received: 23 March 2020 / Approved: 24 March 2020 / Online: 24 March 2020 (06:47:18 CET)

How to cite: Zamai, L. Yin-Yang Balance of ACE/ACE2 Pathways: The Rational for ACE2 Pathway Inhibitor Administration in SARS-CoV-2 Patients. Preprints 2020, 2020030338 (doi: 10.20944/preprints202003.0338.v1). Zamai, L. Yin-Yang Balance of ACE/ACE2 Pathways: The Rational for ACE2 Pathway Inhibitor Administration in SARS-CoV-2 Patients. Preprints 2020, 2020030338 (doi: 10.20944/preprints202003.0338.v1).

Abstract

The article describes the rational for inhibition of the angiotensin-converting enzyme 2 (ACE2) pathways as specific targets in patients infected by SARS-CoV-2.

Supplementary and Associated Material

Subject Areas

Severe Acute Respiratory Syndrome Coronavirus-2; (soluble) ACE2; eosinophil; asthma; IL-10; IL-6; Lung fibrosis; Ang (1-7); hypoxia; infarction; hypertension

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.